Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada clinical trials group study PA.3

Cancer

Volumn 116, Issue 24, 2010, Pages 5599-5607

  Da Cunha Santos, Gilda ^a,b   Dhani, Neesha ^a   Tu, Dongsheng ^c   Chin, Kayu ^a   Ludkovski, Olga ^a   Kamel Reid, Suzanne ^a,b   Squire, Jeremy ^a   Parulekar, Wendy ^c   Moore, Malcolm J ^a,b   Tsao, Ming Sound ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

Author keywords

DNA mutational analysis; epidermal growth factor receptor genes; fluorescence; in situ hybridization; pancreatic neoplasms; protein kinase inhibitors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; K RAS PROTEIN; PLACEBO;

ADULT; ADVANCED CANCER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COPY NUMBER VARIATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MARKER GENE; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANADA; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; GENE DOSAGE; HUMANS; MUTATION; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS; QUINAZOLINES; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 78650095716     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25393     Document Type: Article

References (30)

1. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15: 2403-2413.
2. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA,. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer. 2002; 87: 161-167.
3. Stathopoulos GP, Syrigos K, Aravantinos G, et al. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer. 2006; 95: 587-592.
4. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25: 1960-1966.
5. Parra HS, Cavina R, Latteri F, et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ("Iressa"; ZD1839) in nonsmall-cell lung cancer. Br J Cancer. 2004; 91: 208-212.
6. Hirsch FR, Varella-Garcia M, Cappuzzo F, et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced nonsmall-cell lung cancer patients treated with gefitinib. Ann Oncol. 2007; 18: 752-760. (Pubitemid 46523281)
7. Sakurada A, Shepherd FA, Tsao MS,. Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations. Clin Lung Cancer. 2006; 7 (suppl 4): S138-S144.
8. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med. 2005; 353: 133-144.
9. Holzmann K, Kohlhammer H, Schwaenen C, et al. Genomic DNA-chip hybridization reveals a higher incidence of genomic amplifications in pancreatic cancer than conventional comparative genomic hybridization and leads to the identification of novel candidate genes. Cancer Res. 2004; 64: 4428-4433.
10. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009; 27: 663-671.
11. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359: 1757-1765.
12. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib [serial online]. PLoS Med. 2005; 2: e17.
13. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with nonsmall-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005; 23: 5900-5909.
14. Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR. 21. J Clin Oncol. 2008; 26: 4268-4275.
15. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated nonsmall-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008; 372: 1809-1818.
16. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M,. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988; 53: 549-554.
17. Smit VT, Boot AJ, Smits AM, Fleuren GJ, Cornelisse CJ, Bos JL,. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res. 1988; 16: 7773-7782.
18. Lee J, Jang KT, Ki CS, et al. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer. 2007; 109: 1561-1569.
19. Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS,. K-ras mutations in nonsmall-cell lung carcinoma: a review. Clin Lung Cancer. 2006; 8: 30-38.
20. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in nonsmall-cell lung cancer. J Natl Cancer Inst. 2005; 97: 643-655. (Pubitemid 40812628)
21. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360: 1408-1417.
22. Tzeng CW, Frolov A, Frolova N, et al. Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. Surgery. 2007; 141: 464-469.
23. Rudin CM, Liu W, Desai A, et al. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008; 26: 1119-1127.
24. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced nonsmall-cell lung cancer. J Clin Oncol. 2006; 24: 5034-5042.
25. Hirsch FR, Varella-Garcia M, Dziadziuszko R, et al. Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in nonsmall cell lung cancer. Clin Cancer Res. 2008; 14: 6317-6323.
26. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced nonsmall-cell lung cancer. J Clin Oncol. 2005; 23: 5892-5899.
27. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced nonsmall-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005; 366: 1527-1537.
28. Jimeno A, Tan AC, Coffa J, et al. Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. Cancer Res. 2008; 68: 2841-2849.
29. Varella Garcia M,. Stratification of nonsmall cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay [serial online]. Diagn Pathol. 2006; 1: 19.
30. Varella Garcia M, Diebold J, Eberhard DA, et al. EGFR fluorescence in situ hybridisation assay: guidelines for application to nonsmall-cell lung cancer. J Clin Pathol. 2009; 62: 970-977.